Pancreatic Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 16, 120, 121, 2, 8, 273, 36 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 20, 9, 52 and 6 molecules, respectively.
Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Pancreatic Cancer - Overview
- Pancreatic Cancer - Therapeutics Development
- Pancreatic Cancer - Therapeutics Assessment
- Pancreatic Cancer - Companies Involved in Therapeutics Development
- Pancreatic Cancer - Drug Profiles
- Pancreatic Cancer - Dormant Projects
- Pancreatic Cancer - Discontinued Products
- Pancreatic Cancer - Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/research/gv6zd9/pancreatic_cancer